Both imatinib and low-dose (several nM) dasatinib reinforced CML cell interaction with fibronectin while no significant change was induced in BCR-ABL-negative cells. The gene discussed is FN1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.